Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Meijer

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Neurology|November 1, 1979
Sodium valproate: serial monitoring of EEG and serum levelsA J Rowan, C D Binnie, N K de Beer-Pawlikowski, et al.
Cytometry|November 1, 1986
Extraction of nuclei from selected regions in paraffin-embedded tissueP S Oud, T G Hanselaar, J A Reubsaet-Veldhuizen, et al.
Epilepsia|September 1, 1977
Evaluation of a new immunoassay for determination of phenytoin and phenobarbital: results of a European collaborative control studyD Schmidt, V Goldberg, P J Guelen, et al.
Scandinavian Journal of Gastroenterology|May 8, 1999
High prevalence of celiac disease in apparently healthy blood donors suggests a high prevalence of undiagnosed celiac disease in the Dutch populationK Rostami, C J Mulder, J M Werre, et al.
Epilepsy Research|May 1, 1987
Seven day administration of lamotrigine in epilepsy: placebo-controlled add-on trialC D Binnie, D J Beintema, R M Debets, et al.
Journal of Clinical Pathology|December 1, 2001
MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated formR L ten Berge, F G Snijdewint, S von Mensdorff-Pouilly, et al.
Arzneimittel-Forschung|January 1, 1977
Interlaboratory variability of valproic acid determinationsD Schmidt, B Ferrandes, D Grandjean, et al.
Epilepsia|May 1, 1986
Acute effects of lamotrigine (BW430C) in persons with epilepsyC D Binnie, W van Emde Boas, D G Kasteleijn-Nolste-Trenite, et al.
Inflammatory Bowel Diseases|January 24, 2007
Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's diseaseQiang Gao, Martin J W Meijer, Ulrike G Schlüter, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 3, 2007
Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotypeM J W Meijer, M A C Mieremet-Ooms, A M van der Zon, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Neurology|November 1, 1979
Sodium valproate: serial monitoring of EEG and serum levelsA J Rowan, C D Binnie, N K de Beer-Pawlikowski, et al.
Cytometry|November 1, 1986
Extraction of nuclei from selected regions in paraffin-embedded tissueP S Oud, T G Hanselaar, J A Reubsaet-Veldhuizen, et al.
Epilepsia|September 1, 1977
Evaluation of a new immunoassay for determination of phenytoin and phenobarbital: results of a European collaborative control studyD Schmidt, V Goldberg, P J Guelen, et al.
Scandinavian Journal of Gastroenterology|May 8, 1999
High prevalence of celiac disease in apparently healthy blood donors suggests a high prevalence of undiagnosed celiac disease in the Dutch populationK Rostami, C J Mulder, J M Werre, et al.
Epilepsy Research|May 1, 1987
Seven day administration of lamotrigine in epilepsy: placebo-controlled add-on trialC D Binnie, D J Beintema, R M Debets, et al.
Journal of Clinical Pathology|December 1, 2001
MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated formR L ten Berge, F G Snijdewint, S von Mensdorff-Pouilly, et al.
Arzneimittel-Forschung|January 1, 1977
Interlaboratory variability of valproic acid determinationsD Schmidt, B Ferrandes, D Grandjean, et al.
Epilepsia|May 1, 1986
Acute effects of lamotrigine (BW430C) in persons with epilepsyC D Binnie, W van Emde Boas, D G Kasteleijn-Nolste-Trenite, et al.
Inflammatory Bowel Diseases|January 24, 2007
Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's diseaseQiang Gao, Martin J W Meijer, Ulrike G Schlüter, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 3, 2007
Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotypeM J W Meijer, M A C Mieremet-Ooms, A M van der Zon, et al.
Pageof 7